Wolverine Trading’s Aldeyra Therapeutics ALDX Stock Holding History

Wolverine Trading’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,028	Closed	-$31.1K	–	4594
2025 Q1	$80.2K	Buy	+12,028	New	+$71.1K	﹤0.01%	4286
2023 Q4	–	Sell	-20,266	Closed	-$135K	–	4441
2023 Q3	$135K	Buy	20,266 +2,908	+17%	+$21.6K	﹤0.01%	3896
2023 Q2	$137K	Sell	17,358 -4,649	-21%	-$45.8K	﹤0.01%	3665
2023 Q1	$209K	Buy	+22,007	New	+$156K	﹤0.01%	3363
2022 Q3	–	Sell	-10,309	Closed	-$61.8K	–	4514
2022 Q2	$41K	Buy	+10,309	New	+$35.5K	﹤0.01%	4115

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Wolverine Trading's ALDX Position: Q2 2025 in Review

Wolverine Trading sold out of Aldeyra Therapeutics (ALDX) in Q2 2025, closing a stake of 12,028 shares — an estimated $31.1K sold.

Wolverine Trading first reported a position in ALDX in Q2 2022 and held it in 5 quarters. The position peaked at $209K in Q1 2023. 121 funds tracked by Wall St. Rank hold ALDX as of Q2 2025.

Wolverine Trading reported no remaining Aldeyra Therapeutics position as of Q2 2025 after selling out during the quarter.
Wolverine Trading sold 12,028 Aldeyra Therapeutics shares in Q2 2025, an estimated $31.1K.
Wolverine Trading first reported a position in Aldeyra Therapeutics in Q2 2022 and held it in 5 quarters.
Wolverine Trading's Aldeyra Therapeutics position peaked at $209K in Q1 2023.
121 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2025.

Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.